

AD \_\_\_\_\_

Award Number: DAMD17-01-1-0209

TITLE: Analysis of Apaf-1 and Caspase 9 in Tumorigenesis

PRINCIPAL INVESTIGATOR: Masashi Narita, M.D., Ph.D.

CONTRACTING ORGANIZATION: Cold Spring Harbor Laboratory  
Cold Spring Harbor, New York 11724

REPORT DATE: July 2002

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

**REPORT DOCUMENTATION PAGE**Form Approved  
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

<b>1. AGENCY USE ONLY (Leave blank)</b>		<b>2. REPORT DATE</b> July 2002	<b>3. REPORT TYPE AND DATES COVERED</b> Annual Summary (1 Jul 01 -30 Jun 02)	
<b>4. TITLE AND SUBTITLE</b> Analysis of Apaf-1 and Caspase 9 in Tumorigenesis			<b>5. FUNDING NUMBERS</b> DAMD17-01-1-0209	
<b>6. AUTHOR(S)</b> Masashi Narita, M.D., Ph.D.				
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b>  Cold Spring Harbor Laboratory Cold Spring Harbor, New York 11724  E-Mail: narita@cshl.edu			<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b>  U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			<b>10. SPONSORING / MONITORING AGENCY REPORT NUMBER</b>	
<b>11. SUPPLEMENTARY NOTES</b> report contains color				
<b>12a. DISTRIBUTION / AVAILABILITY STATEMENT</b> Approved for Public Release; Distribution Unlimited				<b>12b. DISTRIBUTION CODE</b>
<b>13. Abstract (Maximum 200 Words) (abstract should contain no proprietary or confidential information)</b> My long-term goal is to identify new components of tumor suppressor networks that are important in breast cancer. My initial proposal focused on apoptosis, and how components of the 'apoptotic machinery' influence breast carcinogenesis and chemotherapeutic responses. For several reasons, these studies were abandoned to focus on cellular senescence. Senescence is a permanent cell cycle arrest program that is conceptually similar to apoptosis and is controlled by the p53, p16, and Rb tumor suppressors (which are important in breast carcinogenesis). I am currently identifying components of the 'senescence machinery' and determining how they suppress proliferation. I have shown that senescence is accompanied by changes in chromatin structure that depend on the p16/Rb tumor suppressor pathway and lead to the repression of growth regulatory genes. I have also generated chimeric mice harboring ES cells with a targeted disruption of one putative component of the silencing program. Future studies will examine the impact of these mechanisms on transformation in vitro and tumorigenesis in vivo, as well as their ability to modulate the cytotoxicity of anticancer drugs. These studies are guided by our understanding of apoptosis, and promise to provide new insights into a new program of tumor suppression in breast cancer.				
<b>14. SUBJECT TERMS</b> senescence, apoptosis, tumor suppression, p53, p16, Rb			<b>15. NUMBER OF PAGES</b> 27	
			<b>16. PRICE CODE</b>	
<b>17. SECURITY CLASSIFICATION OF REPORT</b> Unclassified	<b>18. SECURITY CLASSIFICATION OF THIS PAGE</b> Unclassified	<b>19. SECURITY CLASSIFICATION OF ABSTRACT</b> Unclassified	<b>20. LIMITATION OF ABSTRACT</b> Unlimited	

20021230 158

## **Table of Contents**

<b>Cover</b>	<b>1</b>
<b>SF 298</b>	<b>2</b>
<b>Introduction</b>	<b>4</b>
<b>Body</b>	<b>6</b>
<b>Key Research Accomplishments</b>	<b>10</b>
<b>Reportable Outcomes</b>	<b>11</b>
<b>Conclusions</b>	<b>12</b>
<b>References</b>	<b>13</b>
<b>Appendices</b>	
<b>Figures</b>	<b>15</b>
<b>Figure legends</b>	<b>21</b>
<b>Abstracts</b>	<b>23, 24</b>
<b>Curriculum vitae</b>	<b>25</b>

## Introduction

Our laboratory has long been interested in the process of apoptosis, a process of programmed cell death that can be induced in response to aberrant proliferative signals and many anticancer agents. As a consequence, disruption of apoptosis can lead to tumor progression and drug resistance. In our original application, we proposed to study how apoptosis is executed and the implications of disrupting components of the 'apoptotic machinery' on breast carcinogenesis. Interestingly, senescence is an anti-proliferative program that has many parallels to apoptosis. First, senescence is controlled by important tumor suppressors, including ARF, p53, p16, and Rb, and acts to permanently limit cell proliferation. Second, various stimuli, including oncogenic ras and DNA damage, can induce senescent phenotype, suggesting the existence of a common senescence machinery that contributes to the irreversible nature of the arrest (1-3). Third, senescence functions as an important brake to tumor development and contributes to the action of certain cytotoxic anticancer agents. Together, these observations suggest that senescence parallels apoptosis as an antitumor cellular response to stress. We hypothesize that this process is important in breast cancer development and treatment responses.

As indicated above, senescence appears to involve the Rb and p53 tumor suppressor pathways. Hence, as cells enter a senescent state, p53 and p16 accumulate, and Rb becomes hypophosphorylated. In breast cancer, approximately 50 % of tumors show low or lack of p16 expression, and many have mutations in Rb or p53. It is also significant that cells derived from mammary tissues almost always lose p16 expression when cultured in vitro (4). These observations may be indicating a higher propensity of mammary cells compared to other cell types to inactivate the senescence pathway by loss of p16.

For several reasons (see proposal body), we have abandoned our initial aims to produce mice with defects the p53 effectors Caspase-9 and Apaf-1 to identify and characterize components of the senescence machinery. Specifically, we are interested in how cells initiate and maintain the senescent state, and the role of the p53 and p16/Rb pathways in the process. Based on the established involvement of p53, p16, and Rb in breast carcinogenesis, we hypothesize that cellular senescence is an important mechanisms of tumor suppression that is disrupted during breast cancer development. Moreover, our laboratory has recently shown that a senescence program controlled by p53 and p16 contributes to the outcome of cancer therapy in tumors, and so insights into how

senescence is initiated and maintained may have important implications for understanding drug sensitivity and resistance in breast cancer, and may ultimately help identify better cancer therapies.

Although these experiments differ substantially from our initial proposal, they are conceptually similar in that they are (i) guided by parallels between senescence to apoptosis; (ii) focused on the terminal stage of this anti-proliferative program; (iii) directed towards uncovering new insights into molecular mechanisms of tumor suppression and drug action. Our progress has been substantial, and we are currently writing up the first study that we hope will have a large impact on the field. Although details of our results will be discussed in the 'Body of the Annual Report', it is noteworthy that we have implicated the HP1 proteins in the maintenance phase of senescence. HP1 $\alpha$  is down regulated in a substantial proportion of breast cancers (5), which provides additional links between our studies and breast carcinogenesis. In short, we have based our transition from work on apoptosis to senescence on exciting results, and believe our work is as relevant to breast cancer (if not more) than the studies in our initial proposal.

## **Body of Annual Report**

The ultimate goal of our project is to find uncover the molecular mechanisms of tumor suppression in breast cancer, which include apoptosis and cellular senescence mechanisms. The objectives outlined in my research proposal were designed to elucidate the mechanism of the tumor suppression through the p53-dependent apoptosis pathway, using a genetic approach. Specifically, we proposed to generate conditional knockout mice of Apaf-1, which is downstream target of p53 pathway (6). However, we found that at least 2 groups already generated these mice, putting us at a serious disadvantage. In addition, we obtained some extremely exciting results on the area of cellular senescence. Therefore, we shifted the theme from apoptosis to cellular senescence.

Senescence was initially identified as a permanent form of cell cycle arrest that accompanied the replicative exhaustion of human fibroblasts in culture. However, recent work from our laboratory and elsewhere has shown that senescence is induced by many forms of cellular stress. By analogy to apoptosis, we have been seeking the "common machinery" of cellular senescence. A large body of evidence indicates that both the p53 and Rb tumor suppressor pathways contribute to cellular senescence. Our laboratory and others reported that p53 is required for the induction of 'premature' senescence by oncogenic ras (1, 2, 7). However, p53 is not essential for maintaining senescence (8). On the other hand, there are several lines of observation, which suggests the involvement of epigenetic regulation of gene expression upon senescence (9). Furthermore, we recently found that senescent human fibroblasts exhibit the condensed chromatin structure, which shares heterochromatic features, and that the formation of these structures was strictly dependent on the presence of an intact p16/Rb pathway (Narita et al., in prep). Based on these findings, we hypothesize that epigenetic determination of senescence-specific gene expression pattern may be important for maintaining the stable growth arrest in senescence. Here we focus on our findings so far about cellular senescence and further experimental plans.

### **Characterization of chromatin structure in senescent HDFs**

IMR90s, human diploid fibroblasts (HDFs), induced to senesce by oncogenic Ras, as well as replicative senescent fibroblasts, show a characteristic DAPI staining pattern, exhibiting condensed DAPI-dense foci interspersed throughout the nucleus (Figure 1A). We have designated this as SAHR, Senescence Associated Heterochromatic Regions, because it has heterochromatic features as shown below. First we examined the relationship between SAHRs formation and senescent

phenotype. We have found a close correlation between SAHRs formation and senescent markers such as, cellular morphology and senescence-associated  $\beta$ -galactosidase (SA- $\beta$ -gal) activity (Figure 1B). Furthermore, the adenoviral oncoprotein E1A, which overrides senescence, also inhibits SAHRs formation completely. SAHRs are not found in quiescent cells, indicating SAHRs are not consequence of cell cycle arrest. Taken together, these results indicate that SAHRs could be a new marker of senescence.

To characterize SAHRs, we examined the components of SAHRs, and found that SAHRs are heterochromatic structure. First, HP1 proteins, a family of heterochromatic adaptor molecules involved in epigenetic gene regulation and supra-nucleosomal chromatin structure, colocalized with SAHRs by immunostaining (Figure 2), suggesting that HP1 proteins are involved in SAHRs-formation upon senescence. Interestingly, HP1 $\alpha$  is downregulated in a substantial proportion of breast cancers (5). Next, acetylated histone H3 (K9/14), which is consistent with euchromatin, was clearly excluded from SAHRs (Figure 3). Third, SAHRs colocalized with histone H3 Lys9 methylation (K9M), which provides a binding site for HP1 proteins contributing to proper assembly of heterochromatin (10-12), but did not colocalize with H3 Lys4 methylation (K4M), which was shown to be associated with active chromatin (13, 14) (Figure 3). Histone modification pattern of SAHRs shown here is highly suggestive of transcriptionally inactive chromatin structure.

Heterochromatic features of SAHRs were further confirmed by electron microscopy. Similar to DAPI staining, we identified the well-demarcated regions with relatively high electron density, which is consistent with heterochromatin, in the nuclei of ras-senescent cells, but not in vector control or low serum quiescent cells (Figure 4A-C). Immuno-gold labeling with anti-DNA antibody showed DNA-enrichment in the SAHRs (Figure 4D). Consistently, RNase-gold labeling revealed that RNA was absent from the SAHRs (Figure 4E).

Global level of acetylation of histone H3 was decreased in ras-senescent as well as replicative senescent cells by Western blotting (Figure 5A), while quiescent cells did not show any alterations in the level of H3 K9/14Ac (Figure 5A). E1A again prevented hypo-acetylation of H3 K9/14 in response to oncogenic ras. Consistently, chromatin bound fractions of HP1 $\beta$  and HP1 $\gamma$  were increased in ras-senescent cells compared to vector control and quiescent cells (Figure 5B). E1A abolished the accumulation of HP1 proteins in chromatin fractions in response to oncogenic ras (Figure 5B). Together, these results indicate that oncogenic ras, as well as replicative exhaustion induced distinct chromatin structure, which is a novel type of heterochromatic structure. Furthermore, decrease in global level of H3 acetylation and increase in

chromatin bound HP1s in senescent cells suggest that eu- and heterochromatin redistribution may associate with the process of senescence in human fibroblasts.

p16<sup>INK4a</sup>, which expression is shown to be low or missing in many human cancer cells, including breast cancer, accumulates in senescent cells, and also can induce some features of cellular senescence (4, 14, 15). We asked if p16<sup>INK4a</sup> also induces SAHRs in IMR90s. p16<sup>INK4a</sup> was introduced into IMR90s by retroviral-mediated gene transfer, followed by SA- $\beta$ -gal assay, BrdU incorporation assay, and DAPI staining. Consistent with previous reports, p16<sup>INK4a</sup> induced the senescence phenotype, including SA- $\beta$ -gal activity and low DNA synthesis (Figure 6A). p16<sup>INK4a</sup> also induced SAHRs, which were indistinguishable from the nuclei of ras- or replicative senescent cells (Figure 6B).

### **Regulation of SAHR formation and impact on senescent state**

The data described above demonstrate that alterations in chromatin structure accompany senescence. Recent work has suggested that these changes lead to the repression and/or silencing of growth regulated genes (not shown). Moreover, the adenovirus E1A oncoprotein can interfere with the induction of these structures in a manner that depends in its ability to inactivate Rb, implying that an intact Rb pathway is required for the process. We are currently testing this hypothesis directly using novel 'short-hairpin' RNAs. To this end, we are collaborating with Dr. Greg Hannon (CSHL) to produce retroviral vectors capable of stably suppressing gene expression in fibroblasts and breast epithelial cells. Our preliminary results suggest that this approach will be successful at completely suppressing the expression of genes such as Rb and p16.

### **Generation of HP1 knockout mice**

The putative role of HP1 proteins in maintaining senescence is consistent with a tumor suppressor activity and, consistent with this view, HP1 $\alpha$  is not expressed in a subset of breast cancers (5). In collaboration with Dr. Harald Von Melchner (University of Frankfurt), we have obtained ES cells that have insertional mutations in the HP1 $\alpha$  and HP1 $\beta$  genes. The HP1 $\alpha$ +/- ES cells have produced chimeric mice and the HP1 $\beta$ +/- cells have gone germline. We will use these cells to study the role of HP1 in normal development and in cancer.

### **Future plans**

#### **1. Molecular mechanism of SAHR formation**

To dissect the Rb/p16 and p53 pathway in the SAHRs formation, we will make the retroviral short



hairpin RNAs (shRNA) to obtain the stable silencing. Candidate genes to be silenced include Rb, p16, p53, and HP1s. We will analyze the correlation between chromatin structure and phenotype, or gene expression pattern.

## 2. Chromatin status in the specific genes

To obtain the direct evidence for the epigenetic regulation of gene expression, chromatin immunoprecipitation (ChIP) analysis using antibody against Lys9/14 acetylated histone H3 (euchromatic marker), or Lys9 methylated H3 (heterochromatic marker) will be performed. We will focus on the E2F-target genes, such as cyclin A and PCNA, which are essential for cellular proliferation, and marker genes for senescence, such as stromelysin 1.

## 3. Analysis of mammary epithelial cells.

We will examine epithelial cells for SAHRs and senescence-associated epigenetic changes in gene expression to determine the similarities and differences with fibroblasts. If substantial differences are observed, we will focus on mammary epithelial cells owing to their increased relevance to breast cancer.

## 4. In vivo models

The association between down regulation of HP1 $\alpha$  expression and metastatic phenotype of breast cancer was recently reported. In parallel to our initial proposal on Apaf-1, we will generate mice with targeted disruptions in HP1 $\alpha$  and HP1 $\beta$  (and HP1 $\gamma$  if possible). These animals will be studied for spontaneous cancer formation, and crossed to standard models of breast carcinogenesis (e.g. MMTV-ras).

Based on this Future Plan, new "Statement of Work" will be submitted separately.

### Key Accomplishments

- Ras induced characteristic chromatin structure, SAHRs, which is indistinguishable from replicative senescent cells in IMR90s.
- SAHRs show close correlation with senescent phenotype.
- SAHRs show heterochromatic features.
- E1A prevents SAHRs formation by ras in IMR90s.
- p16<sup>INK4a</sup> also induced SAHRs.

## Reportable Outcomes

### Poster and Abstract

Masashi Narita, Edith Heard, Stephen Hearn, Masako Narita, Scott Lowe; *SAHR, a new marker of senescence, which exhibit heterochromatic features* (poster). 11th International p53 Workshop, Barcelona, Spain, May 15-19, 2002

Masashi Narita, Edith Heard, Stephen Hearn, Masako Narita, Scott Lowe; *Higher order chromatin structure and cellular senescence* (poster). Cancer Genetics and Tumor Suppressor Genes, CSHL, August 14-18, 2002

## **Conclusion**

We have found the novel type of heterochromatic structure (SAHRs) associated with senescence phenotype in human fibroblasts. Rearrangement of chromatin structure is strongly suggestive of the involvement of epigenetic regulation in senescence. One candidate pathway for SAHRs formation is the p16/Rb pathway, at least in part, because E1A blocks the SAHRs and p16 is sufficient to induce SAHRs. Other components of the process involve the HP1 proteins, which may ultimately lead to the silencing of growth related genes. Understanding the molecular mechanism of SAHRs formation and the epigenetic regulation of the specific genes expression in senescence are on ongoing and could contribute to elucidating the "common pathway" of cellular senescence as the machinery of tumor suppression.


## References

1. Serrano M., Lin A.W., McCurrach M.E., Beach D. and Lowe S.W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. *Cell*, 88, 593 (1997)
2. Lin, A. W., Barradas, M., Stone, J. C., van Aelst, L., Serrano, M. & Lowe, S. *Genes Dev.* 12, 3008 (1998)
3. Campisi J. Cellular senescence as a tumor-suppressor mechanism. *Trends Cell Biol* 11, S27 (2001)
4. Brenner, A. J., Stampfer, M. R., Aldaz, C. M. Increased p16 expression with first senescence arrest in human mammary epithelial cells and extended growth capacity with p16 inactivation. *Oncogene* 17, 199 (1998)
5. Kirschmann, D. A., Lininger, R. A., Gardner, L. M., Seftor, E. A., Odero, V. A., Ainsztein, A. M., Earnshaw, W. C., Wallrath, L. L., Hendrix, M. J. Down-regulation of HP1Hsalpha expression is associated with the metastatic phenotype in breast cancer. *Cancer Res* 60, 3359 (2000)
6. Soengas, M. S., Alarcon, R. M., Yoshida, H., Giaccia, A. J., Hakem, R., Mak, T. W., Lowe, S. W. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. *Science* 284, 156 (1999)
7. Lin, A. W., Lowe, S. W. Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation. *Proc Natl Acad Sci U S A* 98, 5025 (2001)
8. Ferbeyre, G., de Stanchina, E., Lin, A. W., Querido, E., McCurrach, M. E., Hannon, G. J., Lowe, S. W. Oncogenic ras and p53 cooperate to induce cellular senescence. *Mol Cell Biol* 22, 3497 (2002)
9. Howard, B. H. Replicative senescence: considerations relating to the stability of heterochromatin domains. *Exp Gerontol* 31, 281 (1996)
10. Nakayama, J., Rice, J. C., Strahl, B. D., Allis, C. D., Grewal, S. I. Role of histone H3 lysine 9 methylation in epigenetic control of heterochromatin assembly. *Science* 292, 110 (2001)
11. Bannister, A. J., Zegerman, P., Partridge, J. F., Miska, E. A., Thomas, J. O., Allshire, R. C., Kouzarides, T. Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. *Nature* 410, 120 (2001)
12. Lachner, M., O'Carroll, D., Rea, S., Mechtler, K., Jenuwein, T. Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins. *Nature* 410, 116 (2001)
13. Litt, M. D., Simpson, M., Gaszner, M., Allis, C. D., Felsenfeld, G. Correlation between histone lysine methylation and developmental changes at the chicken beta-globin locus. *Science* 293, 2453 (2001)


14. Noma, K., Allis, C. D., Grewal, S. I. Transitions in distinct histone H3 methylation patterns at the heterochromatin domain boundaries. *Science* 293, 1150 (2001)
15. You, Y. O., Lee, G., Min, B. M. Retinoic acid extends the in vitro life span of normal human oral keratinocytes by decreasing p16(INK4A) expression and maintaining telomerase activity. *Biochem Biophys Res Commun* 268, 268 (2000)
16. Sandhu, C., Peehl, D. M., Slingerland, J. p16INK4A mediates cyclin dependent kinase 4 and 6 inhibition in senescent prostatic epithelial cells. *Cancer Res* 60, 2616 (2000)

Figure 1

A



B



## Figure 2







Figure 3







Figure 5






Figure 6



## Figure Legends

### Figure 1. Senescence associated nuclear morphology in IMR90s

(A) IMR90s containing empty vector (V), H-RasV12 (Ras), or E1A12S/H-RasV12 (E/R) were stained for SA- $\beta$ -galactosidase activity, followed by DAPI staining, at day 6 postselection. Late passage IMR90s (Sen) and quiescent cells prepared by low serum (LS) were also shown for comparison. Enlarged images of DAPI staining were shown in the lower panels.

(B) Percentage of SA- $\beta$ -gal (left panel) and SAHR (right panel) positive cells at indicated days after selection was scored in IMR90s containing empty vector (V) or H-RasV12 (R). DNA synthesis was monitored by BrdU incorporation (middle panel) at the same time course.

### Figure 2. HP1 proteins colocalize with SAHR

Colocalization of GFP-fused HP1 $\alpha$  or endogenous HP1s (HP1 $\alpha$ ,  $\beta$ , and  $\gamma$ ) and SAHR by laser scanning confocal microscopy. GFP-fused HP1 $\alpha$  was co-expressed with either empty vector (V) or H-RasV12 (Ras) by retroviral gene transfer. Localization of endogenous HP1s was determined by indirect immunofluorescence using the respective antibodies in V, Ras, and replicative senescent cells (Sen). DNA was stained with propidium iodide (PI).

### Figure 3. Modification of histone H3 in senescent IMR90s

Confocal images of histone H3 Lysine 9/14 acetylation (K9/14Ac), Lysine 9 methylation (K9M), and Lysine 4 methylation (K4M) by indirect immunofluorescence using rabbit polyclonal antibodies, in IMR90s expressing empty vector (V) or H-RasV12 (Ras), as well as replicative senescent cells. DNA was counter-stained by propidium iodide (PI).

### Figure 4. DNA/RNA labeling in senescent nuclei of IMR90s

(A-C) Electron microscopy showed the similar condensed chromatin pattern as DAPI staining in ras-senescent cells (Ras), but not in control vector (V) and low serum (LS) quiescent cells. DNA was detected with monoclonal anti-DNA antibody using gold-coupled secondary antibody. (D) Higher magnification view of SAHR in A was shown. (E) RNA was labeled with gold-coupled RNase T1 in the same magnification as D.

### Figure 5. Global level of H3 acetylation or chromatin-bound HP1s

(A) Downregulation of acetylated histone H3 in senescent cells. Equivalent amounts of chromatin-enriched fraction (normalized by cell number) prepared from indicated cells were

subjected to SDS-PAGE for acetylated H3 immunoblotting or Coomassie blue (CBB) staining. As positive controls, young IMR90s were treated with HDAC-inhibitors, sodium butyrate (But; 5mM, 24h), or trichostatin A (TSA; 100ng/ml, 4h). Normal young IMR90s (N), low serum (LS), and confluent cells (conf) were shown for comparison. (B) Representative immunofluorescent image indicating different level of H3 acetylation between nuclei with and without SAHR. (C) Increased level of chromatin-bound HP1 $\beta/\gamma$  in Ras-senescent cells. Chromatin-enriched fraction prepared from the equal number of cells were subjected to Western blotting of HP1 $\alpha$ ,  $\beta$ , and  $\gamma$ . Orc2 Western blot and CBB staining served as loading controls.

**Figure 6. p16 induces SAHRs in IMR90s**

(A, B) IMR90s containing empty vector (V), p16 (p16), and both E1A and p16 (E1A/p16) were assessed for SA-b-galactosidase activity, DAPI staining, and DNA synthesis at day 4 postselection, as in Figure 1.

## Abstract

11th International p53 Workshop,

Title: SAHR, a new marker of senescence, which exhibit heterochromatic features

Masashi Narita, Edith Heard, Stephen Hearn, Masako Narita, Scott Lowe.

Cold Spring Harbor Laboratory

Human diploid fibroblasts (HDFs), such as IMR90s, enter an irreversible growth arrest after a limited number of divisions in culture, known as replicative senescence. Oncogenic ras induces premature senescence, which is phenotypically indistinguishable from replicative senescence. Cellular senescence is accompanied by the accumulation of the tumor suppressors p53 and p16. Both the p53 and p16/Rb pathways must be circumvented for HDFs to escape from senescence.

While characteristic morphological changes in senescent human fibroblasts are well known, the nuclear morphology of senescent cells is poorly characterized. Ras-induced senescent IMR90s, as well as replicative senescent fibroblasts, show a characteristic DAPI staining pattern, which we have designated as SAHR, Senescence Associated Heterochromatic Regions. We have found a close correlation between SAHR formation and senescence markers such as, accumulation of p53/p16 and senescence-associated  $\beta$ -galactosidase activity. Furthermore, the adenoviral oncoprotein E1A, which overrides senescence, also inhibits SAHR formation, and SAHRs are not found in quiescent cells. Taken together, these results indicate that SAHRs are a marker of senescence.

Immunofluorescence studies reveal that SAHRs colocalize with markers of heterochromatin, such as HP1 (heterochromatin protein 1) and Lysine 9 methylated histone H3. In contrast, lysine 9/14 acetylation and lysine 4 methylation of histone H3, which are consistent with euchromatin, are excluded from SAHRs. Electronmicrography confirms similar heterochromatic structures in senescent cells, where DNA is condensed and RNA is absent. Colocalization studies have excluded regions of constitutive heterochromatin, centromere and telomere, as being part of the SAHR, suggesting that SAHRs are a novel type of heterochromatic structure. Given the fact that the levels of acetylated histone H3 are downregulated in senescent cells, our data suggest a global rearrangement of chromatin structure during senescence. If this is true, it could provide a specific gene expression pattern particular to senescence.

## Abstract

Cancer Genetics and Tumor Suppressor Genes

Poster

### HIGHER ORDER CHROMATIN STRUCTURE AND CELLULAR SENESCENCE

Masashi Narita, \*Edith Heard, Stephen Hearn, Masako Narita, Scott Lowe

Cold Spring Harbor Laboratory, Cold Spring Harbor, New York 11724

\*Present address; Centre National de la Recherche scientifique UMR 218, Curie Institute

Human diploid fibroblasts (HDFs), such as IMR90s, enter an irreversible growth arrest after a limited number of divisions in culture, known as replicative senescence. Oncogenic ras induces premature senescence, which is phenotypically indistinguishable from replicative senescence. Cellular senescence is accompanied by the accumulation of the tumor suppressors p53 and p16. Both the p53 and p16/Rb pathways must be circumvented for HDFs to escape from senescence.

While characteristic morphological changes in senescent human fibroblasts are well known, the nuclear morphology of senescent cells is poorly characterized. Ras-induced senescent IMR90s, as well as replicative senescent fibroblasts, show a characteristic DAPI staining pattern, which we have designated as SAHR, Senescence Associated Heterochromatic Regions. We have found a close correlation between SAHR formation and senescence markers such as, accumulation of p53/p16 and senescence-associated  $\beta$ -galactosidase activity. Furthermore, the adenoviral oncoprotein E1A, which overrides senescence, also inhibits SAHR formation, and SAHRs are not found in quiescent cells. Taken together, these results indicate that SAHRs are a marker of senescence.

Immunofluorescence studies reveal that SAHRs colocalize with markers of heterochromatin, such as HP1 (heterochromatin protein 1) and Lysine 9 methylated histone H3. In contrast, lysine 9/14 acetylation and lysine 4 methylation of histone H3, which are consistent with euchromatin, are excluded from SAHRs. Electronmicrography confirms similar heterochromatic structures in senescent cells, where DNA is condensed and RNA is absent. Colocalization studies have excluded regions of constitutive heterochromatin, centromere and telomere, as being part of the SAHR, suggesting that SAHRs are a novel type of heterochromatic structure. Given the fact that the levels of acetylated histone H3 are downregulated in senescent cells, our data suggest a global rearrangement of chromatin structure during senescence. We propose that these alterations produce a characteristic gene expression pattern particular to senescence.



## **CURRICULUM VITAE**

### **IDENTICAL INFORMATION**

Name: Masashi Narita

Home Address: 432 West Main Street, Huntington, NY 11743

Phone & Fax 1-631-421-2707

Business Address: Cold Spring Harbor Laboratory

1 Bungtown Road, James Bld.

Cold Spring Harbor, NY 11724

Phone: 1-516-367-8408

Fax: 1-516-367-8454

E-mail: narita@cshl.org

### **EDUCATIONAL HISTORY**

Mar/1992 M.D. degree Osaka University School of Medicine

Apr/1996 – March/2000 Graduate Student, Department of Surgery,  
Osaka University Graduate School of Medicine

### **PROFESSIONAL BACKGROUND**

May/1992- Dec/1992 Resident in Department of Surgery, Osaka University Hospital

Jan/1993- May/1994 Resident in Department of Surgery, Osaka Police Hospital

June/1994- May/1995 Medical Staff in Department of Surgery, Osaka Police Hospital

June/1995- May/1996 Clinical Fellow, Kinki-Chuo National Hospital

April/2000- pres. Postdoctoral Research, Cold Spring Harbor Laboratory

### **PERSONAL INFORMATION**

Date of Birth: June 19, 1963

Place of Birth: Kyoto, Japan

Nationality: Japanese

Marital Status: Married, 1993

### **LICENSE AND CERTIFICATION**

1990 FMGEMS Basic Component

1991 FMGEMS Clinical Component

1992 Japanese Medical License Registration

## Memberships

The Molecular Biology Society of Japan

Japanese Cancer Association

Japan Surgical Society

## MAJOR RESEARCH INTERESTS

1. apoptosis

2. oncology

## Honors and Awards:

Apr/2000 Uehara Memorial Foundation (Japan), Research fellowship

Jul/2001 Department of Defense, Breast Cancer Research Program

Postdoctoral Fellowship Award

## PUBLICATIONS

### Original articles

1. Narita M, Shimizu S, Ito T, Chittenden T, Lutz RJ, Matsuda H, Tsujimoto Y. Bax interacts with the permeability transition pore to induce permeability transition and cytochrome c release in isolated mitochondria. *Proc Natl Acad Sci USA* 1998 Dec 8; 95(25): 14681-6
2. Shimizu S, Narita M, Tsujimoto Y. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. *Nature* 1999 June 3; 399: 483-7
3. Nomura M, Shimizu S, Ito T, Narita M, Matsuda H, Tsujimoto Y. Apoptotic cytosol facilitates Bax translocation to mitochondria that involves cytosolic factor regulated by Bcl-2. *Cancer Res.* 1999 Nov 1; 59(21): 5542-8.
4. Yamabe K, Shimizu S, Ito T, Yoshioka Y, Nomura M, Narita M, Saito I, Kanegae Y, Matsuda H. Cancer gene therapy using a pro-apoptotic gene, caspase-3. *Gene Ther.* 1999; 6: 1952-9.
5. Satokata I; Tanaka K; Miura N; Narita M; Minaki T; Satoh Y; Kondo S; Okada Y. Three nonsense mutations responsible for group A xeroderma pigmentation. *Mutat Res* 1992 Mar; 278(2): 193-202.
6. Narita M, Nakao K, Ogino N, Nakahara M, Onishi A, Tsujimoto M. Independent prognostic factors in breast cancer patients. *Am J Surg* 1998 Jan; 175(1): 73-5.

7. Narita M, Nishida T, Nakao K, Ogino N et al. Prognostic factors in breast cancer and their limitations. SURGICAL TECHNOLOGY INTERNATIONAL: VIII 1999: 289-94 (review).

8. Narita M, Nakao K, Ogino N, Emoto T, Nakahara M, Yumiba T, Tsujimoto M. A case of Microangiopathic Hemolytic Anemia Associated with Breast Cancer: Improvement with Chemoendocrine Therapy. *Breast Cancer* 1997; 4:39-42.